Hoffmann-la Roche

This early-stage study is testing whether personalized drug combinations can help control advanced colorectal cancer that has spread. Researchers will match patients to specific treatment arms based on genetic markers found in their tumors. The goal is to find safe and effective …

This study follows patients with moderate-to-severe atopic dermatitis (eczema) who participated in earlier trials of afimkibart. It aims to understand the long-term safety and effectiveness of continued treatment. The study will track side effects and measure improvements in skin…

This study is observing how well the drug inavolisib works for people with advanced breast cancer that has a specific genetic mutation and has stopped responding to hormone therapy. Researchers will follow 500 patients in China who are already receiving this treatment as part of …

This large, late-stage study is testing whether a new drug called Afimkibart can help people with moderate to severe ulcerative colitis. Researchers will compare the drug against a placebo in 350 participants to see if it reduces symptoms and improves gut health over 12 weeks. Th…

This study is testing whether adding a new drug called inavolisib to two standard breast cancer medications works better than the standard two-drug combination alone. It's for people with advanced breast cancer that has a specific genetic change (PIK3CA mutation) and is sensitive…

This study is testing a three-drug combination for people with an aggressive type of B-cell lymphoma that has returned or not responded to prior treatment. The main goal is to see if a specific pre-treatment plan can better manage a common side effect called cytokine release synd…

This early-stage study is testing the safety and initial effectiveness of a new drug called inavolisib, both alone and combined with two existing immunotherapy drugs (atezolizumab and pembrolizumab). It's for people with advanced head and neck cancer and other cancers that have a…

This study is testing whether a medication called satralizumab, given as a shot every four weeks, can improve bone strength and muscle function in children with Duchenne muscular dystrophy. The trial includes 50 boys aged 8 to 18 who are already taking daily steroid medication. R…

This early-stage study is testing a new oral medication called RO7763505 to see if it's safe for people. Researchers will give the drug to healthy volunteers and people with stable coronary artery disease to check for side effects and how the body processes it. The study will hel…

This study is testing an experimental drug called Afimkibart for people with moderate to severe rheumatoid arthritis (RA) who haven't gotten enough relief from common advanced treatments. About 160 participants will receive either the new drug or a placebo to see if it safely red…

This study is testing a new weekly injection called RO7795068 to see if it helps people with obesity or overweight and type 2 diabetes lose weight and better control their blood sugar. About 1,600 participants will receive either the active drug or a placebo (dummy injection) for…

This early-stage study is testing the safety and effectiveness of a three-drug combination for people in the US with an aggressive form of lymphoma that has come back or stopped responding to prior treatments. It will enroll about 50 participants who have already tried at least o…

This study allows cancer patients who were in previous Roche-sponsored trials to continue receiving their experimental treatments if they can't access them locally. It's for people who are still benefiting from the treatment and need ongoing therapy. The main goals are to provide…

This study follows 842 people with multiple sclerosis who are receiving subcutaneous (under-the-skin) injections of ocrelizumab. The main goal is to measure how satisfied patients are with this treatment method over 12 months using questionnaires. Researchers will also track bloo…

This study is testing whether a new oral hormone therapy called giredestrant works better than the standard treatment fulvestrant for advanced breast cancer. Both drugs will be given alongside another cancer medication (a CDK4/6 inhibitor). The trial will enroll about 1,050 peopl…

This study aims to understand how the drug risdiplam works in the bodies of very young infants with spinal muscular atrophy (SMA). It will enroll up to 10 newborns under 20 days old to measure the drug's levels in their blood and check for safety. The goal is to gather informatio…

This study has two main goals. First, it will check if the flu virus in children under 12 becomes resistant to the medicine baloxavir. Second, it will see how often the flu spreads from a sick child taking this medicine to other people living in the same house. The study will enr…

This early-stage study aims to check the safety and side effects of a new drug called RO7121932 in people with multiple sclerosis (MS). Researchers will give the drug to 129 participants, first through an IV and then as an injection under the skin, while carefully monitoring for …

This early-stage study is testing the safety and initial effectiveness of combining two different types of immunotherapy drugs for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to standard treatments. The trial will enroll about 121 adults who h…

This study is testing several new drug combinations to find safe and effective treatments for multiple myeloma, a cancer of plasma cells in the bone marrow. It will enroll about 200 adults with the disease, including those whose cancer has come back after previous treatments and …

This study is testing a new drug, RO7204239, to see if it can help the body use insulin more effectively in people with type 2 diabetes who are also overweight or have obesity. It will compare the drug against a placebo (a dummy treatment) in 30 participants over 24 weeks. Resear…

This study is observing patients in real-world clinics who are already receiving a specific cancer immunotherapy (atezolizumab) as an injection under the skin. The main goal is to understand how satisfied patients are with this treatment method and how it affects their quality of…

This study is testing whether a new drug, RO7268489, can help slow the worsening of disability in adults with progressive forms of multiple sclerosis (MS) who are already taking the standard therapy ocrelizumab. About 360 participants will be randomly assigned to receive either t…

This large, late-stage study is testing whether an investigational drug called trontinemab can slow the progression of early Alzheimer's disease. It will involve 800 people with mild cognitive impairment or mild dementia due to Alzheimer's. Participants will receive either the dr…

This study provides continued access to the MS medication ocrelizumab for patients who were already receiving it in previous Roche-sponsored trials. Researchers will track how MS affects participants' physical abilities and daily activities through patient questionnaires. The stu…

This global trial tests whether matching cancer treatments to a patient's specific tumor genetics works better than standard approaches. It's for people with advanced solid tumors that have spread or can't be surgically removed. Participants receive drugs specifically chosen base…

This study compares a new two-drug combination (divarasib + pembrolizumab) against standard chemotherapy for adults with advanced lung cancer that has a specific KRAS G12C mutation and hasn't been treated before. The goal is to see if the new combination helps patients live longe…

This study is testing a new drug called Afimkibart for people with moderate to severe eczema (atopic dermatitis). About 160 participants will receive either the drug or a placebo to see if it safely reduces skin inflammation and itching. The main goal is to see if the drug improv…

This study is testing whether a new medication called afimkibart can help children aged 2-17 who have moderate to severe ulcerative colitis, a painful bowel disease. Researchers want to see if the treatment can bring the disease under control and keep it controlled for a year. Th…

This study is testing whether the drug satralizumab can prevent relapses in people with MOG antibody-associated disease (MOGAD), a rare condition that causes inflammation in the brain and spinal cord. The trial will enroll 152 participants aged 12 and older who have had recent di…

This study is testing a new immune-boosting drug called glofitamab, given alone or with another drug (obinutuzumab), for people with B-cell non-Hodgkin's lymphoma that has come back or hasn't responded to prior treatments. The main goals are to find a safe and effective dose and …

This study is testing how well the drug ocrelizumab works to control multiple sclerosis (MS) in Chinese patients. It will include 60 people with either relapsing or primary progressive forms of MS. The main goals are to see if the drug reduces disease activity and to measure its …

This study is testing whether a new drug called sefaxersen can slow kidney damage in people with IgA nephropathy who are at high risk of their disease getting worse. Researchers will compare the drug to a placebo in 428 participants over about two years to see if it reduces prote…

This study is testing a small, refillable implant placed in the eye that slowly releases a medicine (ranibizumab) for six months. It is being compared to the standard treatment of receiving the same medicine as a monthly injection into the eye. The goal is to see if the implant w…

This study is testing several different immunotherapy drug combinations for people with advanced liver cancer who haven't had prior systemic treatment. The trial is designed to quickly identify which combinations work best and which should be stopped, allowing patients to potenti…

This study is testing if a new continuous glucose monitoring (CGM) system helps adults with type 1 or insulin-dependent type 2 diabetes keep their blood sugar in a healthy range better than the standard finger-prick method. About 270 participants will be randomly assigned to use …

This is an early-stage study to test the safety and tolerability of a new experimental drug, RO7669330, given as an injection into the eye. It is for people with geographic atrophy, an advanced form of age-related macular degeneration that leads to permanent vision loss. The main…

This large, late-stage study is testing whether a new drug called Afimkibart can help people with moderate-to-severe Crohn's disease. It will compare the drug against a placebo in 425 participants to see if it reduces symptoms and improves gut healing. The main goals are to see i…

This study is testing a drug called satralizumab in children aged 2 to 11 who have a rare autoimmune disease called NMOSD, which attacks the nerves in the eyes and spinal cord. The main goal is to see how the drug behaves in children's bodies and to check if it helps prevent dise…

This study is testing whether adding a new drug called inavolisib to standard maintenance therapy helps people with a specific type of advanced breast cancer live longer without their cancer getting worse. It will involve about 230 people whose cancer has spread and has two speci…

This early-stage study is testing a one-time experimental therapy called SPK-10001 for Huntington's disease. Doctors will infuse the therapy directly into specific areas of the brain. The main goals are to see if the treatment is safe and if it can slow the progression of the dis…

This study is testing a small, refillable implant placed in the eye to deliver a steady dose of medication for wet age-related macular degeneration (AMD). The goal is to see if refilling the implant every 36 weeks can maintain vision as effectively as standard monthly or bimonthl…

This early-stage study is testing the safety and initial effectiveness of a new drug, mosunetuzumab, both by itself and in combination with another drug called venetoclax. It is for adults with chronic lymphocytic leukemia (CLL) that has come back or is not responding to current …

This study is testing a new weekly injection, called RO7795068, to see if it helps people with obesity or overweight lose weight and keep it off. It will involve about 2000 adults who do not have type 2 diabetes. The main goal is to see how much body weight participants lose afte…

This study is testing several new combinations of drugs for people with advanced breast cancer that has stopped responding to standard hormone therapies. It aims to find better ways to control the disease and extend life. The trial is enrolling about 316 participants with specifi…

This study is testing two different doses of a new drug, inavolisib, when given with an existing hormone therapy (fulvestrant) for people with a specific type of advanced breast cancer. It aims to see which dose is more effective and safer for patients whose cancer has a PIK3CA m…

This is the first human study of an experimental drug called RO7812653 for early Alzheimer's disease. The main goal is to check if the drug is safe and well-tolerated when given as a single injection into the spinal fluid. The study will enroll about 50 participants with early me…

This study is testing a new drug combination called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if giving these drugs before surgery can safely shrink or eliminate the tumor. The study will enroll a…

This study is testing whether an experimental drug called trontinemab can slow the progression of early Alzheimer's disease. 800 people with mild memory problems or early dementia will receive either the drug or a placebo for 72 weeks. Researchers will measure changes in memory, …

This study is testing an oral medication called fenebrutinib in children and adolescents (ages 10 to under 18) who have relapsing multiple sclerosis (RMS). The main goals are to see how the drug behaves in young bodies, measure its effect on new brain lesions seen on MRI scans, a…

This study is testing an oral drug called alectinib in children and teenagers with advanced solid or brain tumors that have a specific genetic change (ALK fusion) and have not responded to standard treatments. The main goals are to find a safe dose, see how the drug behaves in th…

This study is testing whether adding a new drug called inavolisib to two existing breast cancer drugs works better than the standard two-drug combination. It is for people whose advanced breast cancer has stopped responding to hormone therapy and who have a specific genetic patte…

This large, late-stage study is testing whether a new drug called Afimkibart can help people with moderate-to-severe Crohn's disease. It aims to reduce gut inflammation, relieve symptoms like diarrhea and pain, and help patients achieve remission. The study will involve about 600…

This study is testing a new drug called glofitamab, both by itself and combined with standard chemotherapy, in children and young adults whose aggressive B-cell lymphoma has come back or hasn't responded to prior treatment. The main goals are to see if the treatment is safe and i…

This is an early-stage study to find a safe dose of a new drug called RO7673396 for people with advanced solid tumors that have a specific genetic change called a RAS mutation. The study will first test increasing doses to see what is safe, then test that dose to see if it helps …

This study is testing whether adding a personalized cancer vaccine (autogene cevumeran) to standard immunotherapy (nivolumab) can better prevent cancer from returning in patients with high-risk bladder cancer who have had surgery. The trial will enroll 362 participants who have h…

This study is testing several different combinations of cancer drugs to see which ones work best for people with advanced breast cancer that has spread. It will include nearly 800 participants who have different types of breast cancer and have received different amounts of prior …

This study aims to understand how well the eye injection drug faricimab works and how safe it is in everyday medical practice in China. It will follow 1,000 patients with diabetic macular edema, retinal vein occlusion, or neovascular age-related macular degeneration who are alrea…

This is the first study in people to test a new injectable drug called RO7507062 for systemic lupus erythematosus (SLE). The main goal is to check the drug's safety, side effects, and how it moves through the body in about 70 participants with active lupus. Researchers will test …

This study is testing a new daily medicine called RO7795081 for people with type 2 diabetes. Over 30 weeks, researchers will compare it to a placebo (inactive pill) and an existing diabetes drug to see if it safely lowers long-term blood sugar levels and body weight. The goal is …

This is the first study in humans testing RG6496, a new drug for Huntington's disease. Researchers will give single, increasing doses to 40 people who carry the Huntington's disease gene to check if it's safe and well-tolerated. The study will also measure if the drug reduces the…

This large study is testing whether a new medication called astegolimab can help people with COPD who experience frequent breathing attacks. About 1,290 participants who are former or current smokers with a history of these flare-ups will receive either the drug or a placebo for …

This study is testing whether a medication called emicizumab can safely prevent bleeding episodes in people with a severe, rare form of von Willebrand disease (Type 3). It will compare emicizumab given as a regular preventive treatment against the current standard care, which is …

This large, late-stage study is testing whether an intravenous drug called prasinezumab can slow the worsening of movement problems in people with early Parkinson's disease. It will compare the drug to a placebo in 900 participants who are already on stable Parkinson's medication…

This study is testing a new targeted drug called divarasib, given alone or with other cancer therapies, for people with advanced non-small cell lung cancer (NSCLC) who have a specific genetic change called KRAS G12C and have not yet received any treatment for their advanced disea…

This study is testing an investigational drug called obinutuzumab in children and adolescents with a severe form of lupus that attacks the kidneys, known as lupus nephritis. The goal is to see if the drug can help control the kidney disease and allow patients to reduce their use …

This study is comparing a new drug called glofitamab against standard treatment options for people with mantle cell lymphoma that has returned or stopped responding to previous therapies. Researchers want to see if glofitamab helps patients live longer without their cancer gettin…

This study is testing whether a new two-drug combination (inavolisib plus enzalutamide) works better and is safer than standard treatments for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It will enroll about 100 participants whose …

This early-stage study is testing an investigational drug called cevostamab in a small group of Chinese patients whose multiple myeloma has returned or stopped responding to other treatments. The main goals are to understand how the drug behaves in the body, check its safety, and…

This study is testing if a new version of the MS medication ocrelizumab, given as an injection under the skin, works the same way in the body as the currently available version. About 182 adults with relapsing or primary progressive multiple sclerosis will receive one of the two …

This study is testing an investigational drug called satralizumab for people with two rare autoimmune brain diseases (NMDAR or LGI1 encephalitis). The goal is to see if the drug helps improve patients' daily function and reduces seizures better than a placebo, while monitoring sa…

This study is testing whether the drug risdiplam can help babies and toddlers with spinal muscular atrophy (SMA) who stopped improving or got worse after receiving gene therapy. It will involve 28 children under 2 years old who have two copies of the SMN2 gene. Researchers will m…

This study is checking the long-term safety of a small, permanent implant placed in the eye that slowly releases medication for wet age-related macular degeneration (AMD). It is for people who have already been in related studies testing this device. The main goal is to see if th…

This early-stage study is testing a new drug called NXT007 in males with moderate to severe hemophilia A, including those with and without inhibitors. The main goals are to check if the drug is safe, how it moves through the body, and if it helps reduce bleeding episodes. The stu…

This study is testing if adding the drug risdiplam to babies who have already received gene therapy for spinal muscular atrophy (SMA) is safe and helps them improve their movement skills. It involves about 28 children under 2 years old. Researchers will measure changes in the bab…

This study is following 800 people in China who have had surgery for a specific type of early-stage lung cancer. The goal is to see how well the drug alectinib works at keeping the cancer from coming back when taken after surgery. Researchers will track how long patients stay can…

This study is testing the safety and effectiveness of combining two drugs, mosunetuzumab and lenalidomide, for people with follicular lymphoma, a type of blood cancer. It will involve about 237 participants who have either tried previous treatments or are newly diagnosed but need…

This study is testing a small, refillable implant placed in the eye to continuously deliver a medicine (ranibizumab) for diabetic macular edema, a leading cause of vision loss. It compares getting medicine from this implant every 6 months to receiving a standard eye injection eve…

This study aims to check the long-term safety of a drug called astegolimab for people with chronic obstructive pulmonary disease (COPD). It is for 2,000 participants who have already finished a year-long previous study. The main goal is to monitor for any side effects over an ext…

This study aims to see how well and how safely a treatment called glofitamab works for Chinese adults whose aggressive lymphoma has come back or hasn't responded to their first treatment. It will follow 300 patients who are already planning to receive this therapy as part of thei…

This study aims to develop a simple blood test to help doctors diagnose traumatic brain injuries (TBI) and predict patient recovery. It also seeks to use the test to monitor hospitalized patients for developing complications. The study will enroll 2000 adults who come to the emer…

This study is collecting information on how well the eye injection drug faricimab works for people with wet age-related macular degeneration or diabetic macular edema in real-world doctor's offices. It will follow 850 patients for 2 years to see how their vision changes, how ofte…

This is a large screening study to identify people who might be eligible for future Alzheimer's disease treatment trials. It will enroll 13,000 adults who have noticed memory problems within the last year. Participants will have a blood test and memory assessment to see if they q…

This study is creating a large registry to collect information from 15,000 adults with solid tumor cancers. It aims to understand how detailed genetic testing results relate to the treatments patients receive and their long-term survival. The goal is to gather real-world evidence…

This study is testing a new digital platform designed to help doctors better monitor and manage people with relapsing-remitting multiple sclerosis (MS). The platform includes an app for patients to track their health and a system for doctors to analyze brain scans using artificia…

This early-stage study aims to check the safety and how the body processes an experimental oral medication called RO7795081 in healthy overweight or obese adults. Researchers will give the drug to 40 participants and measure its levels in the blood, while also checking if it affe…

This study aims to gather real-world information about how well standard preventive treatment works for people with severe Type 3 Von Willebrand Disease, a rare bleeding disorder. Researchers will follow 40 patients for at least 24 weeks to track their bleeding episodes and measu…

This study aims to learn more about dry eye disease by observing how various eye tests and biological markers change over time in people who start one of two standard prescription eye drops. It will enroll 350 people, including those with moderate to severe dry eye and healthy vo…

This is a very early, first-in-human study to check if a new drug called RO7806881 is safe for people and to see how the body handles it. The study will give single and multiple doses to 128 healthy volunteers and compare them to people who receive a placebo. The main goal is to …

This study aims to collect genetic information from people with Huntington's Disease to better understand how specific gene variations are linked to the disease-causing mutation. Researchers will enroll 600 participants who will answer questions about their health and provide a s…

This study aims to understand why breast cancer treatments sometimes stop working. Researchers will analyze tumor and blood samples from 320 people with different types of breast cancer whose disease has progressed despite treatment. By comparing samples before and after treatmen…